文献速递免疫规划卫生政策与健康促进

2010-2015年四价脑膜炎球菌CRM结合疫苗(Menveo®)接种后向疫苗不良事件报告系统(VAERS)报告的不良事件

Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.
PubMed 文献 · Vaccine · 2017-03-03

本研究检索2010年1月1日至2015年12月31日VAERS数据库中美国Menveo接种后不良事件报告,共2614份,其中67份为严重报告(含1例死亡),青少年占74%。多数不良事件为非严重且与上市前研究一致,严重报告中最常见为过敏反应和晕厥;未发现新的安全性问题,妊娠期使用未见需关注证据。

要点

  • VAERS共收到2614份Menveo接种后美国报告,67份为严重报告,含1例死亡。
  • 11-18岁青少年占全部报告的74%。
  • 严重报告中最常见的两种事件为过敏反应和晕厥。

核心结论

  • 对VAERS报告的评价显示,Menveo接种后不良事件与上市前研究数据一致。
  • 疫苗提供者应继续强调并遵守正确的疫苗接种操作。

研究设计与样本

  • 研究检索VAERS数据库中2010年1月1日至2015年12月31日美国Menveo接种后不良事件报告。
  • 对严重不良事件、选定的预设结局及妊娠期接种报告进行临床审阅并查阅可用病历。
  • 采用经验贝叶斯数据挖掘识别接种Menveo后报告比例失衡的不良事件。

主要发现

  • 研究期间VAERS共收到2614份Menveo接种后美国报告,其中67份被分类为严重报告,包括1份死亡报告。
  • 11-18岁青少年占全部报告的74%。
  • 多数报告的不良事件为非严重,所描述的不良事件与上市前研究数据一致。
  • 严重报告中最常见的两种事件为过敏反应和晕厥。
  • 审阅超过数据挖掘阈值的不良事件后未发现新的安全性问题,但观察到与不良事件无关的术语报告比例失衡,如「给药剂型错误」和「用药过程操作错误」。

临床怎么用

  • 疫苗提供者应继续强调并遵守正确的疫苗接种操作。

局限性

  • 妊娠期使用Menveo的报告有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data are available describing the post-licensure safety of meningococcal vaccines, including Menveo®. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS) to assess safety in all age groups. METHODS: VAERS is a national spontaneous vaccine safety surveillance system co-administered by the Centers for Disease Control and Prevention and the US Food and Drug Administration. We searched the VAERS database for US reports of adverse events in persons who received Menveo from 1 January 2010 through 31 December 2015. We clinically reviewed reports and available medical records for serious AEs, selected pre-specified outcomes, and vaccination during pregnancy. We used empirical Bayesian data mining to identify AEs that were disproportionately reported after receipt of Menveo. RESULTS: During the study period, VAERS received 2614 US reports after receipt of Menveo. Of these, 67 were classified as serious, including 1 report of death. Adolescents (aged 11-18years) accounted for 74% of reports. Most of the reported AEs were non-serious and described AEs consistent with data from pre-licensure studies. Anaphylaxis and syncope were the two most common events in the serious reports. We did not identify any new safety concerns after review of AEs that exceeded the data mining threshold, although we did observe disproportionate reporting for terms that were not associated with an adverse event (e.g., "incorrect drug dosage form administered", "wrong technique in drug usage process"). Although reports were limited, we did not find any evidence for concern regarding the use of Menveo during pregnancy. CONCLUSIONS: In our review of VAERS reports, findings of AEs were consistent with the data from pre-licensure studies. Vaccine providers should continue to emphasize and adhere to proper administration of the vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Myers TR, McNeil MM, Ng CS, et al. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015. Vaccine. 2017. PMID: 28262331. doi:10.1016/j.vaccine.2017.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。